ERBB2 and prostate cancer: In the present study, we used three complementary approaches to assess the effect of ERBB2- and RAS-overexpression on the metastatic potentials of three metastatic human prostate cancer cell lines and one non-metastatic mouse prostate cancer cell line that have different androgen-sensitivities.